Predictors of health-related quality of life in patients with Crohn’s disease receiving biological therapy

References

• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Knowles SR, Keefer L, Wilding H, et al. Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and Meta-analyses-Part II. Inflamm Bowel Dis. 2018;24(4):742–751.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Whitman CB, R, Spiegel BM, et al. Development of an index to define overall disease severity in IBD n.d. Gut. 2018;67(2):244–254.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-Target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11(5):488–496.
   PubMed Web of Science ®Google Scholar
• Williet N, Sarter H, Gower-Rousseau C, et al. Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients. ECCOJC. 2017;11(2):165–174.
   Web of Science ®Google Scholar
• Van Der Have M, Fidder HH, Leenders M, et al. Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis. 2015;21:369–377.
   PubMed Web of Science ®Google Scholar
• Lesage AC, Hagège H, Tucat G, et al. Results of a national survey on quality of life in inflammatory bowel diseases. Clin Res Hepatol Gastroenterol. 2011;35(2):117–124.
   PubMed Web of Science ®Google Scholar
• Petrak F, Hardt J, Clement T, et al. Impaired health-related quality of life in inflammatory bowel diseases: psychosocial impact and coping styles in a national German sample. Scand J Gastroenterol. 2001;36(4):375–382.
   PubMed Web of Science ®Google Scholar
• Ae JH, Turunen U, Risto AE, et al. Impact of Demographic Factors, Medication and Symptoms on Disease-Specific Quality of Life in Inflammatory Bowel Disease. Qual Life Res. 2009;18(8):961–9.
   PubMed Web of Science ®Google Scholar
• Christiansen T. Organization and financing of the Danish health care system. Health Policy. 2002;59(2):107–118.
   PubMed Web of Science ®Google Scholar
• BIOIBD. National annual report 2017-2018 2019. 2021. https://www.sundhed.dk/content/cms/66/102866_bioibd_aarsrapport2018-2019_endelig.pdf. (accessed March 15, 2021).
   Google Scholar
• Kjeldsen J, Thorsgaard N, Nielsen R, et al. The Danish national registry for biological therapy in inflammatory bowel disease. Clin Epidemiol. 2016;8:607–612.
   PubMed Web of Science ®Google Scholar
• Rasmussen B, Haastrup P, Wehberg S, et al. Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy. Scand J Gastroenterol. 2020;55(6):656–663.
   PubMed Web of Science ®Google Scholar
• RADS. Baggrundsnotat for dyre laegemidler til behandling af kroniske inflammatoriske tarmsygdomme n.d. https://medicinraadet.dk/media/5793/rev-lmr_gastro_33.pdf., (accessed April 25, 2019).
   Google Scholar
• BIOIBD. National annual report 2016-2017 2018. https://docplayer.dk/106156662-National-aarsrapport.html. (accessed March 15, 2021).
   Google Scholar
• Walsh AJ, Bryant RV, Travis SPL. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13(10):567–579.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of CD activity. Lancet. 1980;1:514.
   PubMed Web of Science ®Google Scholar
• Stjernman H, Grännö C, Järnerot G, et al. Short health scale: a valid, reliable, and responsive instrument for subjective health assessment in Crohn’s disease. Inflamm Bowel Dis. 2008;14:47–52.
   PubMed Web of Science ®Google Scholar
• Casellas F, Herrera-de Guise C, Robles V, et al. Patient preferences for inflammatory bowel disease treatment objectives. Dig Liver Dis. 2017;49(2):152–156.
   PubMedGoogle Scholar
• Bojic D, Bodger K, Travis S. Patient reported outcome measures (PROMs) in inflammatory bowel disease: new data. J Crohn’s Colitis. 2017;11(suppl_2):S576–S585.
   Google Scholar
• Casellas F, Vivancos JL, Sampedro M, et al. Relevance of the phenotypic characteristics of Crohn's disease in patient perception of health-related quality of life . Am J Gastroenterol. 2005;100(12):2737–2742.
   PubMed Web of Science ®Google Scholar
• Burisch J, Weimers P, Pedersen N, Cukovic-Cavka S, Vucelic B, Kaimakliotis I, et al. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease-an ECCO-EpiCom study. J Crohns Colitis. 2014;8(9):1030–1042.
   PubMed Web of Science ®Google Scholar
• Palm Ø, Bernklev T, Moum B, et al. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J Rheumatol. 2005;32:1755–1759.
   PubMed Web of Science ®Google Scholar
• Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. J Crohn’s Colitis. 2013;7(6):467–473.
   Google Scholar
• Huppertz-Hauss G, Lie Høivik M, Jelsness-Jørgensen LP, et al. Health-related quality of life in patients with inflammatory bowel disease 20 years after diagnosis: Results from the IBSEN study. Inflamm Bowel Dis. 2016;22(7):1679–1687.
   PubMed Web of Science ®Google Scholar
• Tabibian A, Tabibian JH, Beckman LJ, et al. Predictors of health-related quality of life and adherence in Crohn’s disease and ulcerative colitis: implications for clinical management. Dig Dis Sci. 2015;60(5):1366–1374.
   PubMed Web of Science ®Google Scholar
• Gibson PR, Weston AR, Shann A, et al. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn’s disease. J Gastroenterol Hepatol. 2007;22(8):1306–1312.
   PubMed Web of Science ®Google Scholar
• Perera LP, Bhandari S, Liu R, et al. Advanced age does not negatively impact Health-Related quality of life in inflammatory bowel disease. Dig Dis Sci. 2018;63(7):1787–1793.
   PubMed Web of Science ®Google Scholar
• Harland NJ, Dawkin MJ, Martin D. Relative utility of a visual analogue scale vs a six-point Likert scale in the measurement of global subject outcome in patients with low back pain receiving physiotherapy. Physiotherapy. 2015;101(1):50–54.
   PubMed Web of Science ®Google Scholar
• Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12(8):1246–1256.e6.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency E. Guideline on the development of new medicinal products for the treatment of Crohn’s Disease (Draft) 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-development-new-medicinal-products-treatment-crohns-disease-revision-2_en.pdf. (accessed June 13, 2019).
   Google Scholar
• (RKKP) TDNCR. RKKP-Research Access n.d. https://www.rkkp-forskningsadgang.dk/users/sign_in. (accessed August 19, 2021).
   Google Scholar